Literature DB >> 22918632

Lack of immunoglobulins does not prevent C1q binding to RGC and does not alter the progression of experimental glaucoma.

Qiong J Ding1, Amy C Cook, Alina V Dumitrescu, Markus H Kuehn.   

Abstract

PURPOSE: The degeneration of retinal ganglion cells (RGC) in the glaucomatous retina is accompanied by activation of the classical complement cascade. The purpose of this study was to evaluate whether complement component C1q binding and activation of the complement cascade in the glaucomatous retina requires the presence of immunoglobulins.
METHODS: Experimental glaucoma was induced in normal mice and those carrying a targeted deletion of the RAG1 gene. Binding of C1q to RGC and accumulation of C3 and C5b-9 was investigated using immunohistochemical and proteomic approaches. Damage to the optic nerve and RGC was determined and compared between the two strains. Complement activation and accumulation were also evaluated in vitro using dissociated retinal cell cultures.
RESULTS: C1q was detected in the RGC layer in both RAG1(-/-) and control mice with elevated IOP, but not in mice with normal IOP. Proteomic analysis of retinal membrane fractions indicated that C1q and C3 are membrane bound to a similar degree in RAG1(-/-) and control mice with elevated IOP. The absence of Ig does not affect the rate of axonal damage or RGC loss. Furthermore, cultured RGC maintained in serum-free media are also C1q and C3 immunoreactive, demonstrating that Ig is not required for C1q binding to damaged RGC.
CONCLUSIONS: Our data demonstrate that lack of immunoglobulins and mature T/B cells does not influence the progression of glaucoma. Furthermore, immunoglobulins do not appear to be required for C1q binding and complement cascade activation on damaged RGC. These findings suggest that C1q recognizes an alternative binding partner expressed by stressed RGC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22918632      PMCID: PMC3465017          DOI: 10.1167/iovs.12-10442

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  46 in total

Review 1.  Regional immunity and ocular immune privilege.

Authors:  J W Streilein
Journal:  Chem Immunol       Date:  1999

2.  RAGE binds C1q and enhances C1q-mediated phagocytosis.

Authors:  Wanchao Ma; Vivek Rai; Barry I Hudson; Fei Song; Ann Marie Schmidt; Gaetano R Barile
Journal:  Cell Immunol       Date:  2012-02-13       Impact factor: 4.868

3.  Serum autoantibody biomarkers for age-related macular degeneration and possible regulators of neovascularization.

Authors:  Kei Morohoshi; Nishal Patel; Masaharu Ohbayashi; Victor Chong; Hans E Grossniklaus; Alan C Bird; Santa J Ono
Journal:  Exp Mol Pathol       Date:  2011-10-06       Impact factor: 3.362

4.  Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies.

Authors:  M Botto; C Dell'Agnola; A E Bygrave; E M Thompson; H T Cook; F Petry; M Loos; P P Pandolfi; M J Walport
Journal:  Nat Genet       Date:  1998-05       Impact factor: 38.330

5.  Neurodegenerative and inflammatory pathway components linked to TNF-α/TNFR1 signaling in the glaucomatous human retina.

Authors:  Xiangjun Yang; Cheng Luo; Jian Cai; David W Powell; Dahai Yu; Markus H Kuehn; Gülgün Tezel
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-31       Impact factor: 4.799

6.  New insights into autoantibody profiles from immune privileged sites in the eye: a glaucoma study.

Authors:  Nils Boehm; Dominik Wolters; Uta Thiel; Ulrike Lossbrand; Nelli Wiegel; Norbert Pfeiffer; Franz H Grus
Journal:  Brain Behav Immun       Date:  2011-08-06       Impact factor: 7.217

Review 7.  The case for autoimmunity in glaucoma.

Authors:  Martin B Wax
Journal:  Exp Eye Res       Date:  2010-08-27       Impact factor: 3.467

8.  Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex.

Authors:  R William Vandivier; Carol Anne Ogden; Valerie A Fadok; Peter R Hoffmann; Kevin K Brown; Marina Botto; Mark J Walport; James H Fisher; Peter M Henson; Kelly E Greene
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

9.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

Authors:  Anders Heijl; M Cristina Leske; Bo Bengtsson; Leslie Hyman; Boel Bengtsson; Mohamed Hussein
Journal:  Arch Ophthalmol       Date:  2002-10

Review 10.  Complement and systemic lupus erythematosus.

Authors:  Mark J Walport
Journal:  Arthritis Res       Date:  2002-05-09
View more
  14 in total

1.  Transplantation of iPSC-derived TM cells rescues glaucoma phenotypes in vivo.

Authors:  Wei Zhu; Oliver W Gramlich; Lauren Laboissonniere; Ankur Jain; Val C Sheffield; Jeffrey M Trimarchi; Budd A Tucker; Markus H Kuehn
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

2.  Retinal Ganglion Cell Axon Regeneration Requires Complement and Myeloid Cell Activity within the Optic Nerve.

Authors:  Sheri L Peterson; Yiqing Li; Christina J Sun; Kimberly A Wong; Kylie S Leung; Silmara de Lima; Nicholas J Hanovice; Kenya Yuki; Beth Stevens; Larry I Benowitz
Journal:  J Neurosci       Date:  2021-08-20       Impact factor: 6.167

3.  Clusterin and complement activation in exfoliation glaucoma.

Authors:  Ivo Doudevski; Agueda Rostagno; Mary Cowman; Jeffrey Liebmann; Robert Ritch; Jorge Ghiso
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-17       Impact factor: 4.799

4.  Apoptotic retinal ganglion cell death in an autoimmune glaucoma model is accompanied by antibody depositions.

Authors:  Stephanie C Joachim; Christine Mondon; Oliver W Gramlich; Franz H Grus; H Burkhard Dick
Journal:  J Mol Neurosci       Date:  2013-10-03       Impact factor: 3.444

5.  Immunoproteomic analysis of potential serum biomarker candidates in human glaucoma.

Authors:  Gülgün Tezel; Ivey L Thornton; Melissa G Tong; Cheng Luo; Xiangjun Yang; Jian Cai; David W Powell; Joern B Soltau; Jeffrey M Liebmann; Robert Ritch
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-13       Impact factor: 4.799

Review 6.  Immune regulation toward immunomodulation for neuroprotection in glaucoma.

Authors:  Gülgün Tezel
Journal:  Curr Opin Pharmacol       Date:  2012-10-19       Impact factor: 5.547

7.  Adoptive transfer of immune cells from glaucomatous mice provokes retinal ganglion cell loss in recipients.

Authors:  Oliver W Gramlich; Qiong J Ding; Wei Zhu; Amy Cook; Michael G Anderson; Markus H Kuehn
Journal:  Acta Neuropathol Commun       Date:  2015-09-15       Impact factor: 7.801

8.  Cryopreserved Mesenchymal Stromal Cells Maintain Potency in a Retinal Ischemia/Reperfusion Injury Model: Toward an off-the-shelf Therapy.

Authors:  Oliver W Gramlich; Anthony J Burand; Alex J Brown; Riley J Deutsch; Markus H Kuehn; James A Ankrum
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

9.  Immune response after intermittent minimally invasive intraocular pressure elevations in an experimental animal model of glaucoma.

Authors:  Oliver W Gramlich; Julia Teister; Mareike Neumann; Xue Tao; Sabine Beck; Harald D von Pein; Norbert Pfeiffer; Franz H Grus
Journal:  J Neuroinflammation       Date:  2016-04-18       Impact factor: 8.322

10.  Exercise reverses age-related vulnerability of the retina to injury by preventing complement-mediated synapse elimination via a BDNF-dependent pathway.

Authors:  Vicki Chrysostomou; Sandra Galic; Peter van Wijngaarden; Ian A Trounce; Gregory R Steinberg; Jonathan G Crowston
Journal:  Aging Cell       Date:  2016-09-09       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.